Argentina Lab Closures: Four Labs Lose Sanitary Authorization
Argentine Regulator Suspends four Pharmaceutical Companies
Argentina’s National Administration of Medicines, Food and Medical Technology (Anmat) revoked the operating licenses of four pharmaceutical companies for operating without a qualified technical director, according to an official notice published in the Official Bulletin on January 15, 2026.
Details of the Suspension
The Anmat initiated these actions following a systematic control process that revealed deficiencies in the companies’ operations. The agency’s Registry of Establishment Registration identified the lack of a technical director as a critical violation of regulatory standards. These suspensions formalize measures initially announced in november 2025.
While the names of the four companies were not immediately released in the initial report, anmat indicated further details would be available through its official channels. The agency’s decision underscores its commitment to ensuring the safety and efficacy of pharmaceutical products available to the public.
Anmat’s Regulatory Authority
Anmat is the Argentine government agency responsible for regulating and controlling medicines, food, and medical technology.It operates under the Ministry of Health and is tasked with protecting public health by ensuring that products meet established quality, safety, and efficacy standards. The agency conducts inspections, audits, and laboratory analyses to verify compliance with regulations.
In 2024,Anmat issued Resolution 1488/2024,outlining the requirements for technical directors in pharmaceutical companies,emphasizing their role in overseeing quality control and ensuring adherence to good manufacturing practices. Resolution 1488/2024